- Home
- SABS vs RDI Comparison
SABS vs RDI Comparison
Compare SABS & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- RDI
- Stock Information
- Founded
- SABS 2014
- RDI 1937
- Country
- SABS United States
- RDI United States
- Employees
- SABS N/A
- RDI N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- SABS Health Care
- RDI Consumer Discretionary
- Exchange
- SABS Nasdaq
- RDI Nasdaq
- Market Cap
- SABS 31.2M
- RDI 31.6M
- IPO Year
- SABS N/A
- RDI N/A
- Fundamental
- Price
- SABS $4.09
- RDI $1.31
- Analyst Decision
- SABS Strong Buy
- RDI
- Analyst Count
- SABS 3
- RDI 0
- Target Price
- SABS $9.00
- RDI N/A
- AVG Volume (30 Days)
- SABS 203.1K
- RDI 33.6K
- Earning Date
- SABS 11-13-2025
- RDI 11-14-2025
- Dividend Yield
- SABS N/A
- RDI N/A
- EPS Growth
- SABS N/A
- RDI N/A
- EPS
- SABS N/A
- RDI N/A
- Revenue
- SABS $114,698.00
- RDI $211,292,000.00
- Revenue This Year
- SABS N/A
- RDI $6.85
- Revenue Next Year
- SABS N/A
- RDI $10.86
- P/E Ratio
- SABS N/A
- RDI N/A
- Revenue Growth
- SABS N/A
- RDI 7.11
- 52 Week Low
- SABS $1.00
- RDI $1.17
- 52 Week High
- SABS $6.60
- RDI $1.87
- Technical
- Relative Strength Index (RSI)
- SABS 71.11
- RDI 49.28
- Support Level
- SABS $3.68
- RDI $1.18
- Resistance Level
- SABS $4.15
- RDI $1.33
- Average True Range (ATR)
- SABS 0.31
- RDI 0.07
- MACD
- SABS 0.04
- RDI 0.00
- Stochastic Oscillator
- SABS 93.18
- RDI 64.29
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.